Information  X 
Enter a valid email address

ShieldTherapeutics Ord1.5P (STX)

Date Time Source Announcement
07 Jan 2022 7:00 am
RNS
Investor Presentation
05 Jan 2022 7:00 am
RNS
Licence Agreement in Canada for Accrufer?
30 Dec 2021 9:06 am
RNS
Second Price Monitoring Extn
  9:00 am
RNS
Price Monitoring Extension
29 Dec 2021 11:05 am
RNS
Second Price Monitoring Extn
  11:00 am
RNS
Price Monitoring Extension
16 Dec 2021 11:05 am
RNS
Second Price Monitoring Extn
  11:00 am
RNS
Price Monitoring Extension
  7:00 am
RNS
Patient Access Expands for Accrufer?
07 Oct 2021 9:45 am
EQS
Shield Therapeutics (STX) Life Sciences Investor Forum research
30 Sep 2021 5:30 pm
RNS
Block Listing 6 Monthly Return
27 Sep 2021 7:00 am
RNS
Jose A. Menoyo Appointed as Chief Medical Officer
21 Sep 2021 7:00 am
RNS
Investor presentation
23 Aug 2021 7:00 am
RNS
PDMR Transaction Notification
20 Aug 2021 11:08 am
EQS
Shield Therapeutics (STX) - Focused on US market penetration
17 Aug 2021 7:00 am
RNS
Half-year Report
12 Aug 2021 7:25 am
EQS
Hardman & Co Video Event | Shield Therapeutics plc - Investor Forum
  7:00 am
RNS
Licence agreement secured in Republic of Korea
11 Aug 2021 7:00 am
RNS
Notice of Results
09 Aug 2021 7:00 am
RNS
AEGIS-CKD study results published in AJKD
04 Aug 2021 4:41 pm
RNS
Second Price Monitoring Extn
  4:35 pm
RNS
Price Monitoring Extension
  2:05 pm
RNS
Second Price Monitoring Extn
  2:00 pm
RNS
Price Monitoring Extension
24 Jun 2021 7:00 am
RNS
US launch of Accrufer? confirmed for July 1, 2021
23 Jun 2021 4:40 pm
RNS
Second Price Monitoring Extn
  4:35 pm
RNS
Price Monitoring Extension
21 Jun 2021 1:35 pm
RNS
Investor presentation
18 Jun 2021 7:00 am
RNS
Directorate Change
17 Jun 2021 2:30 pm
RNS
Results of 2021 Annual General Meeting
15 Jun 2021 6:15 pm
RNS
Grant of share options to the CEO
28 May 2021 7:00 am
RNS
Appointment of new Chief Executive Officer
  7:00 am
RNS
Total Voting Rights
26 May 2021 10:35 am
EQS
Shield Therapeutics (STX): Accrufer launch on schedule
21 May 2021 7:00 am
RNS
US update
18 May 2021 7:00 am
RNS
AEGIS-H2H study results published in IBD
17 May 2021 7:00 am
RNS
Commencement of trading on the OTCQX Best Market
13 May 2021 3:00 pm
RNS
2020 Annual Report and 2021 AGM Notice
10 May 2021 7:00 am
RNS
Appointment of Two Non-Executive Directors
06 May 2021 1:44 pm
RNS
Total Voting Rights Update
29 Apr 2021 7:00 am
RNS
Preliminary Results
22 Apr 2021 7:00 am
RNS
Notice of Results
07 Apr 2021 9:33 am
RNS
Holding(s) in Company
  9:31 am
RNS
Holding(s) in Company
06 Apr 2021 11:05 am
RNS
Second Price Monitoring Extn
  11:00 am
RNS
Price Monitoring Extension
  7:00 am
RNS
Holding(s) in Company
31 Mar 2021 3:01 pm
RNS
Total Voting Rights Update
  3:00 pm
RNS
Block Listing 6 Monthly Return
30 Mar 2021 7:00 am
RNS
Investor presentation
26 Mar 2021 7:00 am
RNS
Study demonstrates effectiveness of ferric maltol
24 Mar 2021 5:40 pm
RNS
Block Listing Application
23 Mar 2021 5:53 pm
RNS
Holding(s) in Company
  12:23 pm
RNS
Holding(s) in Company
22 Mar 2021 7:00 am
RNS
Shield appoints new Chief Financial Officer
18 Mar 2021 2:02 pm
RNS
Result of General Meeting & Open Offer
15 Mar 2021 5:21 pm
RNS
Holding(s) in Company
09 Mar 2021 7:00 am
RNS
Australia's TGA approves Feraccru
05 Mar 2021 4:54 pm
RNS
PDMR Transaction Notification

a d v e r t i s e m e n t